Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Location
26 Landsdowne Street, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.28K % +16.8%
Debt-to-equity 7.1 % -16.9%
Return On Equity -32.2 % -340%
Return On Assets -30 % -346%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.1M shares +0.33%
Common Stock, Shares, Outstanding 54.1M shares +0.32%
Entity Public Float 309B USD +88.7%
Common Stock, Value, Issued 54K USD 0%
Weighted Average Number of Shares Outstanding, Basic 62.6K shares +0.3%
Weighted Average Number of Shares Outstanding, Diluted 62.6K shares +0.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.4M USD -25.9%
General and Administrative Expense 29.1M USD -24.6%
Operating Income (Loss) -81.5M USD -168%
Net Income (Loss) Attributable to Parent -71.1M USD -297%
Earnings Per Share, Basic -1 USD/shares -280%
Earnings Per Share, Diluted -1 USD/shares -250%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 47.1M USD -35.2%
Other Assets, Current 69K USD
Assets, Current 206M USD -23%
Property, Plant and Equipment, Net 3.17M USD -24.8%
Operating Lease, Right-of-Use Asset 4.61M USD -23.4%
Other Assets, Noncurrent 9K USD -88.2%
Assets 215M USD -23%
Accounts Payable, Current 2.86M USD -29.3%
Employee-related Liabilities, Current 2.95M USD -22.8%
Liabilities, Current 11.6M USD -19.8%
Operating Lease, Liability, Noncurrent 4.66M USD -33.5%
Other Liabilities, Noncurrent 197K USD 0%
Liabilities 16.5M USD -24.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 241K USD -36.4%
Retained Earnings (Accumulated Deficit) -574M USD -14.1%
Stockholders' Equity Attributable to Parent 198M USD -22.9%
Liabilities and Equity 215M USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.3M USD +39.7%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -777K USD -102%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 54.1M shares +0.32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16M USD -211%
Deferred Tax Assets, Valuation Allowance 51.8M USD -68.5%
Deferred Tax Assets, Gross 54.7M USD -67.3%
Depreciation 1.27M USD -29%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -71.3M USD -328%
Property, Plant and Equipment, Gross 18.5M USD +2.02%
Operating Lease, Liability, Current 2.35M USD +10%
Deferred Tax Assets, Operating Loss Carryforwards 1.44M USD -98.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.9M USD +17.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%